Anzeige
Mehr »
Login
Dienstag, 11.03.2025 Börsentäglich über 12.000 News von 690 internationalen Medien
Warum diese Aktie jetzt die Chance auf +100 % Kurspotenzial hat!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40Z30 | ISIN: US29970R3030 | Ticker-Symbol:
NASDAQ
10.03.25
15:42 Uhr
1,780 US-Dollar
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
EVAXION BIOTECH A/S ADR Chart 1 Jahr
5-Tage-Chart
EVAXION BIOTECH A/S ADR 5-Tage-Chart

Aktuelle News zur EVAXION BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
04.03.Evaxion Biotech: Evaxion to present at numerous upcoming conferences213Evaxion will provide company and scientific updates at conferences in both the US and Europe during the coming weeks and months COPENHAGEN, Denmark, March 4, 2025 - Evaxion Biotech A/S (NASDAQ:...
► Artikel lesen
04.03.Evaxion Biotech A/S - 6-K, Report of foreign issuer-
25.02.Evaxion Biotech: Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package298Originally planned as a two-year study, the trial has been extended by an additional year to collect three-year clinical outcome data The additional third year of EVX-01 dosing may provide further insights...
► Artikel lesen
25.02.Evaxion Biotech A/S - 6-K, Report of foreign issuer2
14.02.Evaxion re-establishes compliance with Nasdaq minimum stockholders' equity requirement2
EVAXION BIOTECH Aktie jetzt für 0€ handeln
14.02.Evaxion secures Nasdaq listing with equity boost4
14.02.Evaxion Biotech: Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination291Evaxion will remain listed on Nasdaq after successfully evidencing compliance with the Nasdaq minimum stockholders' equity requirement Evaxion has restored its equity above the minimum requirement through...
► Artikel lesen
12.02.Evaxion Biotech A/S - 6-K, Report of foreign issuer-
31.01.Evaxion Biotech: Evaxion announces closing of $10.8 million public offering330COPENHAGEN, Denmark, January 31, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, today announced the...
► Artikel lesen
30.01.Evaxion Biotech: Evaxion announces pricing of $10.8 million public offering322COPENHAGEN, Denmark, January 30, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, today announced the...
► Artikel lesen
28.01.Evaxion Biotech A/S - F-1/A, Registration statement for certain foreign private issuers-
28.01.Evaxion granted 180-day compliance extension by Nasdaq3
28.01.Evaxion Biotech: Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement270Following a constructive Nasdaq hearing panel on January 7, 2025, Evaxion has been granted a 180-day extension in relation to the Nasdaq minimum equity requirementEvaxion has currently restored its...
► Artikel lesen
27.01.Evaxion Biotech A/S - 6-K, Report of foreign issuer2
15.01.Evaxion Biotech Completes Dosing In Phase 2 Trial For Personalized Cancer Vaccine EVX-011
15.01.Evaxion Biotech: Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01376Trial remains on track for completion and data readout in the second half of 2025 COPENHAGEN, Denmark, January 15, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio...
► Artikel lesen
14.01.Evaxion Biotech: Evaxion announces completion of ADS ratio change388COPENHAGEN, Denmark, January 14, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, today...
► Artikel lesen
14.01.Evaxion Biotech A/S - 6-K, Report of foreign issuer-
10.01.Evaxion Biotech: Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change292COPENHAGEN, Denmark, January 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, today announced that...
► Artikel lesen
07.01.Evaxion Biotech A/S - 6-K, Report of foreign issuer-
Seite:  Weiter >>
79 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1